CN117981747B - Cell freezing solution and application thereof in cell preparation - Google Patents
Cell freezing solution and application thereof in cell preparation Download PDFInfo
- Publication number
- CN117981747B CN117981747B CN202410406620.9A CN202410406620A CN117981747B CN 117981747 B CN117981747 B CN 117981747B CN 202410406620 A CN202410406620 A CN 202410406620A CN 117981747 B CN117981747 B CN 117981747B
- Authority
- CN
- China
- Prior art keywords
- cell
- solution
- cells
- cryopreservation
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000007710 freezing Methods 0.000 title claims abstract description 35
- 230000008014 freezing Effects 0.000 title claims abstract description 35
- 238000005138 cryopreservation Methods 0.000 claims abstract description 87
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 69
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 69
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 69
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 108090000190 Thrombin Proteins 0.000 claims abstract description 31
- 229960004072 thrombin Drugs 0.000 claims abstract description 31
- 239000000463 material Substances 0.000 claims abstract description 15
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 277
- 239000000243 solution Substances 0.000 claims description 129
- 239000000203 mixture Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000001110 calcium chloride Substances 0.000 claims description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 229920002307 Dextran Polymers 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007853 buffer solution Substances 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 238000002659 cell therapy Methods 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 claims description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 claims description 2
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
- 229910001622 calcium bromide Inorganic materials 0.000 claims description 2
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 claims description 2
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 229940093181 glucose injection Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 239000006285 cell suspension Substances 0.000 abstract description 19
- 239000007788 liquid Substances 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 238000011065 in-situ storage Methods 0.000 abstract description 4
- 239000000499 gel Substances 0.000 description 81
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000011550 stock solution Substances 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 229940086319 nattokinase Drugs 0.000 description 10
- 108010073682 nattokinase Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 238000004321 preservation Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 4
- 229960002713 calcium chloride Drugs 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 239000002577 cryoprotective agent Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000004987 nonapoptotic effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- XIAYFENBYCWHGY-UHFFFAOYSA-N 2-[2,7-bis[[bis(carboxymethyl)amino]methyl]-3-hydroxy-6-oxoxanthen-9-yl]benzoic acid Chemical compound C=12C=C(CN(CC(O)=O)CC(O)=O)C(=O)C=C2OC=2C=C(O)C(CN(CC(O)=O)CC(=O)O)=CC=2C=1C1=CC=CC=C1C(O)=O XIAYFENBYCWHGY-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure provides a gel-forming cell cryopreservation solution comprising dimethyl sulfoxide, a soluble calcium salt, and thrombin. When the cell cryopreservation liquid is used for cryopreserving cells, the cells can maintain activity under the low-temperature condition. The cell suspension recovered by using the cell freezing solution is directly mixed with fibrinogen, so that in-situ gel forming can be realized, a cell preparation wrapped by gel materials can be obtained, and the loss of cells caused by liquid loss is reduced. Meanwhile, the gel can maintain the activity of cells in the gel, so that better efficacy exertion is realized.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a cell freezing solution and application thereof in a cell preparation.
Background
Cell therapy refers to a therapeutic method for treating a disease or improving physiological functions by implantation of autologous or allogenic cells. Compared with small molecular drugs, large molecular drugs and protein drugs, the biggest characteristic of cell therapy is that living cells are used as drugs, so that the cell therapy has higher requirements on preservation of cell activity. With rapid development of biotechnology and in-depth knowledge of cellular properties, cell therapy has rapidly progressed and is widely used in clinical practice, particularly in the fields of autoimmune diseases, degenerative diseases, cardiovascular diseases, tumors, and the like.
Cell therapy drugs that have been applied clinically can be classified into fresh cell preparations and frozen cell preparations in terms of preservation conditions of the cell drugs. Wherein, the fresh cell preparation refers to clinical application after cells in the culture and expansion process are subjected to digestion and washing steps and resuspended by using physiological simulation solution and buffer solution. The frozen cell preparation is prepared by suspending the cultured and amplified cells in frozen solution, and preserving at low temperature (generally below-80deg.C) to stop enzyme activity in the cells completely and stop cell metabolism activity, thereby realizing long-term preservation of cells. Before use, the frozen cells can be placed in an environment with the temperature not higher than 37 ℃ for thawing recovery, and then clinical application is carried out. In theory, the fresh cell preparation is directly used without the process of cryopreservation and resuscitation, and has the characteristics of high cell activity rate and better cell function. Accordingly, fresh cell preparations have extremely high requirements on the temperature and humidity of the preservation environment, and most of them require special preservation solutions to provide balanced conditions and nutrient systems for the cells. Even under such conditions, the preservation time of the cells is not more than 72 hours in many cases. The geographical range of applicability of fresh cell preparations is therefore limited. On the other hand, the time required for the projects such as sterile detection, mycoplasma detection, virus detection and the like in the cell medicine release test is longer and is 14-180 days, and the validity period of the fresh cell preparation is far exceeded. These test items therefore require a risk release before the result is not achieved, increasing the risk to the patient to some extent.
Cell cryopreservation formulations can solve this problem to some extent. When the cells are frozen, cryoprotectants such as glycerol or dimethyl sulfoxide are used, and can improve the permeability of cell membranes to water, so that the water in the cells is not easy to form sharp ice crystals at low temperature, and the damage of the sharp ice crystals to the cells is reduced. The cells can be stored for several years or even decades under cryopreservation conditions, during which time there is sufficient time for adequate stability studies of the cryopreservation system. In addition, the freezing condition can be maintained by liquid nitrogen or dry ice, and the frozen state can be transported to a place far from the preparation place without additional power input maintenance. Therefore, the frozen cell preparation has larger application space in the geographic range. Of course, cell cryopreservation formulations present advantages as well as a number of attendant problems. Firstly, the frozen stock solution needs to be added with a permeable or non-permeable cryoprotectant, and the substances often have certain cytotoxicity or tissue toxicity, so that when the frozen stock preparation is clinically applied, the frozen stock preparation needs to be diluted or washed to a certain extent to reduce the toxicity of the cryoprotectant. Secondly, the cell activity of frozen cells is mostly lower than that of fresh cells, so that the frozen solution needs to be subjected to detailed formula research to ensure that the frozen solution can maintain the effects of cell viability, apoptosis and the like in the aspect of freezing.
Cell drugs can be morphologically divided into cell suspensions and non-cell suspensions. The cell suspension is prepared by re-suspending cells in physiological simulation solution or buffer solution. Non-cellular suspensions are understood to mean tissue engineering methods, in which cells are combined with a material or, by means of a defined culture, form cell aggregates, after which the cells are applied. For example, the cartilage repair techniques ACI and MACI approved by the united states drug administration are autologous chondrocyte suspensions, injected into cartilage defect sites, and tightly covered by periosteum or collagen membrane to prevent loss of autologous chondrocytes, thereby achieving in-situ cartilage repair. But at present, after chondrocytes are combined with a scaffold material by a certain tissue engineering method, such as CartiOne ™, the chondrocytes are directly transplanted to a cartilage defect part, so that the loss of the chondrocytes can be directly avoided. At present, except for immune cells used for treating tumor diseases, the administration is mostly carried out through intravenous infusion. Stem cells and terminally differentiated somatic cells are used in clinical applications for the treatment of autoimmune diseases, degenerative diseases, and cardiovascular diseases. Part of the application scenes more require that cells stay locally and function for a longer period of time. In this case, bonding with the material is a possible option.
The form of a material will have a direct impact on its function, properties and application. The materials reported in the prior literature and clinical studies are porous materials, fibrous materials, gel materials and the like. The gel material has certain fluidity, can better adapt to the shapes of different application parts, and has good application prospect. It has also been reported that cytosolic drugs bound to gel materials can remain inside tissues for longer periods of time, thereby exerting greater efficacy.
Disclosure of Invention
The present disclosure provides a cell cryopreservation solution capable of forming a gel, which can maintain the activity of cells under low temperature conditions when the cells are cryopreserved. The cell freezing solution contains thrombin, and the principle that fibrin and thrombin form gel is utilized, so that the cell suspension is directly mixed with fibrinogen after recovery, in-situ gel forming can be realized, a cell preparation wrapped by gel materials can be obtained, and the loss of cells along with the loss of liquid is reduced. Meanwhile, the gel can maintain the activity of cells in the gel, so that better efficacy exertion is realized.
An aspect of the present disclosure provides a cell cryopreservation solution comprising dimethyl sulfoxide, a soluble calcium salt, and thrombin.
In the present disclosure, non-cytotoxic thrombin is added to a cell cryopreservation solution as an impermeable cryoprotectant to reduce the concentration of dimethyl sulfoxide with cell and tissue toxicity. Meanwhile, the DMSO is not removed by the cell cryopreservation liquid in a cleaning mode, so that the convenience of using the cell cryopreservation preparation is improved.
In some embodiments, the concentration of dimethyl sulfoxide in the cell cryopreservation solution is 0.01% (v/v) to 10% (v/v), e.g., can be 0.01% (v/v), 0.05% (v/v), 0.1 (v/v), 0.5 (v/v), 1 (v/v), 2 (v/v), 4 (v/v), 6 (v/v), 8 (v/v), 10 (v/v), or any value therebetween. In some preferred embodiments, the concentration of dimethyl sulfoxide in the cell cryopreservation solution is 0.01% (v/v) to 5% (v/v), more preferably 0.01% (v/v) to 3% (v/v).
In some embodiments, the concentration of thrombin in the cell cryopreservation solution is 1-100 IU/mL, e.g., 1 IU/mL、2 IU/mL、5 IU/mL、10 IU/mL、20 IU/mL、30 IU/mL、40 IU/mL、50 IU/mL、60 IU/mL、70 IU/mL、80 IU/mL、90 IU/mL、100 IU/mL or any value therebetween. In some preferred embodiments, the concentration of thrombin in the cell cryopreservation solution is 2-50 IU/mL, more preferably 5-25 IU/mL.
In some embodiments, the concentration of the soluble calcium salt in the cell cryopreservation solution is 1-60 mM, which may be, for example, 1mM, 5mM, 10 mM, 15 mM, 20 mM, 30 mM, 40 mM, 50mM, 60 mM or any value therebetween. In some preferred embodiments, the concentration of the soluble calcium salt in the cell cryopreservation solution is 1-20 mM.
In some embodiments, the thrombin source may be human fibrinogen, thrombin of other animal species, such as bovine thrombin, rabbit thrombin, murine thrombin, sheep thrombin, porcine thrombin, and thrombin of other species origin, or a mixture of two or more thrombin.
In some embodiments, the soluble calcium salt comprises one or more of calcium chloride, calcium bromide, calcium nitrate, calcium chlorate, calcium perchlorate, calcium bicarbonate, and calcium dihydrogen phosphate. Preferably, the soluble calcium salt is calcium chloride.
In some embodiments, the cell cryopreservation solution further comprises at least one of a permeable cryopreservation protectant, a non-permeable cryopreservation protectant, a buffer solution, and a physiological solution.
In some embodiments, the buffer solution comprises a phosphate buffer solution, a HEPES buffer solution, or Hank's buffer solution.
In some embodiments, the physiological solution comprises physiological saline or dextrose injection.
In some embodiments, the permeable cryopreservation protective agent comprises propylene glycol or ethanol.
In some embodiments, the impermeable cryopreservation protective agent comprises albumin, trehalose, dextran, polyethylene glycol, dextran, sucrose, hydroxyethyl starch.
In some embodiments, the cell cryopreservation solution comprises dimethyl sulfoxide, calcium chloride, thrombin, glucose, dextran, glycerol, and albumin.
In some embodiments, the cell cryopreservation solution comprises 0.01-10% (v/v) dimethyl sulfoxide, 1-60 mmol/L calcium chloride, 1-100 IU/mL thrombin, 0.01-0.5 mmol/L glucose, 1-10% (w/v) dextran, 0.01-5% (v/v) propylene glycol, and 1-10% (w/v) albumin.
In some embodiments, the cell cryopreservation solution comprises 0.01-3% (v/v) dimethyl sulfoxide, 1-20 mmol/L calcium chloride, 2-50 IU/mL thrombin, 0.1-0.3 mmol/L glucose, 2-8% (w/v) dextran, 0.5-2% (v/v) propylene glycol, and 2-8% (w/v) albumin.
In some embodiments, the cell cryopreservation solution further comprises a phosphate buffer solution. In some embodiments, the phosphate buffer solution comprises 120-180 (e.g., 120, 140, 160, 180) mmol/L sodium chloride, 0.5-5 (e.g., 0.5, 1, 1.5, 2, 2.5, 2.68, 3, 3.5, 4, 4.5, 5) mmol/L potassium chloride, 0.5-5 (e.g., 0.5, 1, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5) mmol/L potassium dihydrogen phosphate, and 1-20 (e.g., 1, 5, 10, 15, 20) mmol/L disodium hydrogen phosphate. In some embodiments, the phosphate buffer solution further comprises 0.05-5 (e.g., 0.05, 0.1, 0.5, 1,2, 3, 4, 5) mmol/L magnesium ions.
Another aspect of the present disclosure provides the use of the cell cryopreservation solution for cryopreserving cells or for forming a gel material.
In some embodiments, the cell density in the cell cryopreservation solution is 1×10 7/mL~5×107/mL, e.g., 1×10 7/mL、2×107/mL、3×107/mL、4×107/mL、5×107/mL or any value in between. Preferably, the cell density in the cell cryopreservation solution is 1X 10 7/mL~3×107/mL.
In some embodiments, the gel material is encapsulated with cells.
In some embodiments, the cells comprise stem cells.
In some embodiments, the cells comprise mesenchymal stem cells.
In some embodiments, the cells comprise adipose mesenchymal stem cells, bone marrow mesenchymal stem cells, or umbilical cord mesenchymal stem cells.
Yet another aspect of the present disclosure provides a composition for forming a gel, the composition comprising the cell cryopreservation solution and a fibrinogen solution.
In some embodiments, the fibrinogen solution comprises fibrinogen and a solvent.
In some embodiments, the fibrinogen concentration in the fibrinogen solution is 5-100 mg/mL, e.g., 5 mg/mL, 10 mg/mL, 20 mg/mL, 30 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, 70 mg/mL, 80 mg/mL, 90 mg/mL, 100 mg/mL, or any value therebetween. Preferably, the fibrinogen concentration in the fibrinogen solution is 10-75 mg/mL, more preferably 30-60 mg/mL.
In some embodiments, the mixing volume ratio of the cell cryopreservation solution to the fibrinogen solution is 1: (0.5-2), for example, 1:0.5, 1:0.75, 1:1, 1:1.25, 1:1.5, 1:1.75, 1:2, or any value therebetween. Preferably, the mixing volume ratio of the cell freezing solution to the fibrinogen solution is 1: (0.8-1.2).
In some embodiments, the solvent comprises physiological saline, water for injection, or phosphate buffered solution.
In some embodiments, the fibrinogen source may be human fibrinogen, or fibrinogen of other animal species, such as bovine fibrinogen, rabbit fibrinogen, murine fibrinogen, sheep fibrinogen, pig fibrinogen, or fibrinogen of other species, or a mixture of two or more fibrinogen.
In some embodiments, the fibrinogen and thrombin species may be the same or different.
In yet another aspect of the present disclosure, a cell preparation prepared from the composition is provided.
In some embodiments, the cell preparation is in the form of a gel.
In some embodiments, the cells in the cell preparation are encapsulated by a gel. Preferably, more than 90% of the cells in the cell preparation are encapsulated by the gel.
In some embodiments, the cells comprise stem cells.
In some embodiments, the cells comprise mesenchymal stem cells.
In some embodiments, the cells comprise adipose mesenchymal stem cells, bone marrow mesenchymal stem cells, or umbilical cord mesenchymal stem cells.
Yet another aspect of the present disclosure provides a method for preparing the cell preparation, comprising mixing the cell cryopreservation solution in which cells are frozen with the fibrinogen solution after thawing, to form a gel.
In some embodiments, the mixing volume ratio of the cell cryopreservation solution to the fibrinogen solution is 1: (0.5-2), for example, 1:0.5, 1:0.75, 1:1, 1:1.25, 1:1.5, 1:1.75, 1:2, or any value therebetween. Preferably, the mixing volume ratio of the cell freezing solution to the fibrinogen solution is 1: (0.8-1.2).
In some embodiments, the disclosure also provides the use of the cell cryopreservation solution, the composition, the cell preparation, or the cell preparation obtained by the preparation method in the preparation of a medicament for cell therapy.
In some embodiments, the cell therapy drug is used to treat autoimmune diseases, degenerative diseases, cardiovascular diseases, tumors.
The technical scheme of the invention has the following beneficial effects:
1. The cell freezing solution can provide low-temperature preservation for cells for more than 6 months.
2. The cell frozen by the cell frozen stock solution can form a stable gel structure with fibrinogen solution after being recovered.
3. After the cells frozen by the cell frozen stock solution are recovered, a stable gel structure can be formed with the fibrinogen solution, and the cells in the formed gel can still keep activity.
4. After the cells frozen by the cell frozen stock solution are recovered, a stable gel structure can be formed with the fibrinogen solution, and the gel structure can wrap most cells (> 90%).
5. The cell frozen by the cell frozen stock solution can form a stable gel structure with fibrinogen solution after being recovered. The processes of cell cryopreservation, cell resuscitation and gel structure formation can not cause massive cell death and massive cell apoptosis.
6. The cell frozen by the cell frozen stock solution can form a stable gel structure with the fibrinogen solution after being recovered, and the cell can survive stably in the gel.
Drawings
Figure 1 shows a statistical plot of toxicity of DMSO at different concentrations for adipose-derived mesenchymal stem cells of three different donors after 24 hours of continuous culture.
Figure 2 shows a statistical plot of toxicity of DMSO at different concentrations for adipose-derived mesenchymal stem cells of three different donors after 72 hours of continuous culture.
FIG. 3 shows a statistical plot of the time required for gel formation of cell cryopreservation solutions of varying concentrations of thrombin, calcium chloride, DMSO content with varying concentrations of fibrinogen solution.
Figure 4 shows a statistical plot of cell viability after 3 months and 6 months of cryopreservation of adipose-derived mesenchymal stem cells from three different donors in the cryopreservation solution of the present invention.
Figure 5 shows a photograph of the macroscopic morphology of the gel formed by the cell cryopreservation solution.
FIG. 6 shows fluorescence microscopy images after thawing of cells after cryopreservation in a cryopreservation solution, after gel formation with fibrinogen solution, after dead staining of cells in the gel.
Figure 7 shows a statistical plot of the proportion of cells contained in the gel after resuscitating after cryopreservation in a cryopreservation solution, forming a gel with fibrinogen solution.
FIG. 8 shows a statistical plot of cell viability in gels after recovery of cells after cryopreservation in cryopreservation solution, and after formation of gels with fibrinogen solution.
Figure 9 shows a statistical plot of the proportion of non-apoptotic cells in the gel after resuscitating cells after cryopreservation in a cryopreservation solution, forming a gel with fibrinogen solution.
FIG. 10 shows fluorescence microscopy pictures after thawing of cells after cryopreservation in a cryopreservation solution, after gel formation with fibrinogen solution, and further incubation for 24 hours, after dead staining of cells in the gel.
Detailed Description
The present invention will be described in further detail with reference to the following examples and the accompanying drawings, in order to make the objects, technical solutions and advantages of the present invention more apparent. The specific embodiments described herein are for purposes of illustration only and are not to be construed as limiting the invention in any way. In addition, in the following description, descriptions of well-known structures and techniques are omitted so as not to unnecessarily obscure the concepts of the present disclosure. Such structures and techniques are also described in a number of publications.
The experimental methods in the following examples are conventional methods unless otherwise specified.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
Among them, thrombin, calcium chloride and fibrinogen were purchased from Shanghai Laiyes blood products Co.
Phosphate buffer (pH 7.2-7.4) was purchased from Beijing Soy Bao technology Co., ltd., P1020.
Dextran was purchased from Cord pharmaceutical Condition, national drug standard H22021777.
Albumin was purchased from aladine, B265993.
Nattokinase purchased from Sian Tian Guangdong Biotechnology Co., ltd., T1025.
Cell basal medium was purchased from sammer femto technology (china), C12571500BT.
Fetal bovine serum was purchased from sammer feishier technology (china), C0235.
The cell complete medium is cell basal medium+10% fetal bovine serum.
Example 1
The cell cryopreservation solution is used for low-temperature preservation of cells and comprises a cryopreservation protective agent, a buffer solution or a physiological solution, calcium chloride, thrombin and the like. When the cell cryopreservation liquid is used for cryopreserving cells, the cells can maintain activity under the low-temperature condition. The cell suspension is directly mixed with fibrinogen after recovery, so that in-situ gel formation can be realized. Wherein the fibrinogen solution is composed of fibrinogen and corresponding solvent.
The use process comprises two steps of freezing and gelling.
The freezing step is to mix the cells with the cell freezing solution, then put the mixture into a freezing tube, and cool the cells to below-80 ℃ for preservation by a program cooling box or a program cooling instrument.
The gel forming step is to mix the frozen cells with fibrinogen solution in a ratio of 1:1 to form gel after the frozen cells are melted rapidly.
1. Dimethyl sulfoxide (DMSO) concentration exploration test
DMSO can enter the cell through the cell membrane, and can avoid the formation of larger ice crystals in the cell to puncture the cell in the freezing process, so that the cell-free preparation is a common permeable freezing protective agent. But it has some cytotoxicity. When it becomes part of the cell product, it is necessary to control the concentration or to remove it by washing. The cell cryopreservation liquid does not remove DMSO in a cleaning mode, so that convenience in use of the cell cryopreservation preparation is ensured. Therefore, the cell can continue to grow in the gel containing DMSO after the frozen stock solution forms the gel by exploring the tolerable DMSO concentration range of the cell through the test, thereby exerting the efficacy.
Three different donor adipose-derived mesenchymal stem cells were seeded in 96-well plates, respectively, with 4000 cells per well. After incubation for 24 hours. All wells inoculated with cells were equally divided into 8 groups of 6 duplicate wells per sample. Cell complete media containing different concentrations of DMSO (0.1%, 0.2%, 0.5%, 0.8%, 1.0%, 2.0%, 5.0%, v/v) were added to wells of each group as experimental groups, and medium groups without DMSO were used as control groups. After further incubation for 24 hours and 72 hours, each group of cells was assessed for activity using the CCK-8 kit.
The specific method is that a culture medium is used for diluting the CCK-8 reagent by 10 times to prepare working solution. The medium in each well was then aspirated, 100uL of this working solution was added and incubated with cells for 100 min at 37 ℃. Wells without cells in the wells were designated as blank and incubated under the same conditions. And finally, measuring the absorbance of each hole at 450 nm by using an enzyme-labeling instrument, wherein the absorbance of an experimental group is marked as an A measured value, the absorbance of a control group is marked as an A control value, and the absorbance of a blank group is marked as an A blank value. The cell viability calculation method comprises the following steps: cell viability (%) = (a measured value-a blank value)/(a control value-a blank value) ×100%.
The results of evaluating the cell activities of adipose-derived mesenchymal stem cells of three different donors are shown in fig. 1-2. When the DMSO content in the environment is more than 2%, the cell activity is obviously reduced. When the DMSO content in the environment is 2%, the cell activity is maintained to be more than 90% after 24 hours, but the cell activity is obviously reduced to be less than 50% after 72 hours. When the DMSO content in the environment is less than or equal to 2%, the effect on the cell activity is not great. From this test result, it was determined that the final gel product formed had a DMSO concentration in the range of 0.01% to 5%, a sub-optimal range of 0.01% to 2.5%, and an optimal range of 0.01% to 1.5%. According to the reverse thrust of the gel forming process, the concentration range of DMSO in the frozen stock solution is 0.01-10%, the suboptimal range is 0.01-5%, and the optimal range is 0.01-3%.
2. Thrombin, calcium chloride, fibrinogen concentration discovery assay
The concentration of thrombin, calcium chloride, DMSO and fibrinogen in the fibrinogen solution in the cell cryopreservation solution have an important effect on the rate of gel formation, so that it is necessary to explore their appropriate concentrations by experimentation, as well as the concentrations in the corresponding cryopreservation solution and fibrinogen.
Frozen stock solutions and fibrinogen solutions were prepared according to the orthogonal test designs of table 1 below.
Wherein the frozen stock solution is prepared by dissolving phosphate buffer solution (pH 7.2-7.4), and other components are added into glucose (0.15 mmol/L), dextran (5%, w/v), glycerol (1%, v/v) and albumin (5%, w/v).
The fibrinogen solution dissolves fibrinogen using physiological saline.
Adipose-derived mesenchymal stem cells of three different donors were resuspended in a cryopreservation solution, the cell density was adjusted to 2×10 6/mL, and then mixed with an equal volume of fibrinogen solution to form a gel. Continuous measurements of absorbance at 350 nm were performed with an microplate reader during gel formation, automatically scanned every 10 seconds. The absorbance curve was analyzed and when the slope of the curve was 0, the gel was completely formed, and the time for complete gel formation was recorded. As a result, as shown in FIG. 3, the gel forming time was varied from 5 seconds to 150 seconds for each of the above groups. The effect levels of fibrinogen concentration in the thrombin, calcium chloride, DMSO and fibrinogen solutions on gel formation time were also calculated using SUMIF functions, respectively. Among the factors studied, the calcium chloride concentration has the greatest effect on the gel time, followed by thrombin concentration, DMSO concentration, fibrinogen concentration in that order.
According to the test result, the concentration of the thrombin in the cell freezing solution is in the range of 1-100 IU/mL, the suboptimal range is 2-50 IU/mL, and the optimal range is 5-25 IU/mL. The concentration of calcium chloride in the gel in the cell freezing solution is in the range of 1-60 mM, the suboptimal range is 1-20 mM, and the optimal range is 2-10 mM.
From this test result, it can be obtained that the fibrinogen concentration in the fibrinogen solution is in the range of 5-100 mg/mL, the suboptimal range is 10-75 mg/mL, and the optimal range is 30-60 mg/mL.
Example 2
The basic solvent of the cell cryopreservation solution prepared in this example is water, and the composition formula is shown in table 2 below:
and (3) placing the prepared cell frozen stock solution in a refrigerator at the temperature of 2-8 ℃ for precooling and preserving.
The adipose-derived mesenchymal stem cells of three different donors were cultured using a cell complete medium under culture conditions of 37 ℃,5% CO 2 concentration and complete humidity, and the cell confluency was about 85% as observed by microscope. Cells were then collected by digestion with recombinant trypsin (TryplE) and cell viability and cell density were calculated by acridine orange/propidium iodide (AO/PI) staining.
According to the cell counting result, taking 1.2×10 8 of living cells, centrifugally collecting, removing supernatant, slowly adding 6 mL of prepared cell freezing solution into cell sediment, uniformly mixing to uniformly disperse the cells in the cell freezing solution, wherein the cell density is 2×10 7/mL.
The cell suspension was aliquoted into 6 cryopreservation tubes, 1 mL per tube.
The frozen tube was placed in a program cooling box (Corning, coolCell) and then the program cooling box was placed in a-80 ℃ low temperature refrigerator. And taking the cell cryopreservation tube out of the program cooling box after 24 hours, and storing in a low-temperature refrigerator at the temperature of-80 ℃.
Sampling at 3 months and 6 months respectively, taking out the freezing tube from the refrigerator, placing the freezing tube into a water bath kettle at 37 ℃ for rapid melting, and then carrying out cell density and cell activity detection analysis. The results obtained are shown in FIG. 4. When the cell density of frozen storage is 2X 10 7 cells/mL, the cell viability of the adipose-derived mesenchymal stem cells of three different donors is above 90% after 6 months of frozen storage.
Example 3
The basic solvent of the cell cryopreservation solution prepared in this example is water, and the composition formula is shown in table 3 below:
and (3) placing the prepared cell frozen stock solution in a refrigerator at the temperature of 2-8 ℃ for precooling and preserving.
Adipose-derived mesenchymal stem cells were cultured in the same manner as in example 2, and the cell confluency was about 85% as observed by a microscope. Cells were then collected by digestion with recombinant trypsin (TryplE) and cell viability and cell density were calculated by acridine orange/propidium iodide (AO/PI) staining.
According to the cell counting result, taking the living cells 6×10 7, centrifugally collecting, removing the supernatant, slowly adding 3 mL prepared cell freezing solution into the cell sediment, uniformly mixing to uniformly disperse the cells in the cell freezing solution, wherein the cell density is 2×10 7/mL.
The cell suspension was aliquoted into 3 cryopreservation tubes, 1 mL per tube.
And placing the freezing tube in a program cooling box, and then placing the program cooling box in a low-temperature refrigerator at-80 ℃. And taking the cell cryopreservation tube out of the program cooling box after 24 hours, and storing in a low-temperature refrigerator at the temperature of-80 ℃.
Sampling at 6 months, taking out the frozen storage tube from the refrigerator, and rapidly melting in a water bath kettle at 37 ℃.
A fibrinogen solution was prepared as shown in table 4 below, with water as the solvent:
1 mL of the formulated fibrinogen solution was aspirated into a2 mL syringe.
The thawed 1 mL cell suspension was aspirated into another 2 mL syringe.
Two syringes were placed on a plastic holder of a twin mixer and connected to a Y-extension tube, while pushing out the two components to form a gel completely free of flow in about 5 minutes. The macroscopic morphology of the gel is shown in figure 5.
Example 4
Cell cryopreservation solutions were prepared under the conditions of example 3. Adipose mesenchymal stem cells were cryopreserved according to a cryopreservation density of 2X 10 7/mL. Sampling and resuscitating after 6 months of freezing.
A fibrinogen solution was prepared according to the conditions of example 3.
The resuscitated cell suspension and fibrinogen solution were removed using a twin mixer as described in example 3 to provide a gel containing cells.
Cell-containing gels were visualized by staining using Calcein/propidium iodide (Calcein-AM/PI) cell activity and toxicity detection kit (Beyotime, C2015M), where Calcein-AM was able to permeate cell membranes and hydrolyze with cell endogenous esterases to produce the polar molecule Calcein (Calcein) with strong negative charge that is unable to permeate cell membranes, and thus is retained in the cells, where Calcein emits strong green fluorescence. PI dyes do not cross the cell membrane of living cells, but bind to DNA within dead cells where the cell membrane integrity is compromised, exhibiting red fluorescence. The use of Calcein-AM/PI dye allows the cell-encapsulated gel to appear green on fluorescent microscopy and red on dead cells. The staining results are shown in fig. 6. The results showed that the vast majority of cells were living cells within the gel (stained green) and only a very small number of cells were dead cells (stained red).
Example 5
Cell cryopreservation solutions were prepared under the conditions of example 3. Adipose-derived mesenchymal stem cells were frozen at a frozen density of 2X 10 7/mL and 3X 10 7/mL, respectively. Sampling and resuscitating after 6 months of freezing.
A fibrinogen solution was prepared according to the conditions of example 3.
The resuscitated cell suspension and fibrinogen solution were removed using a twin mixer as described in example 3 to provide a gel containing cells.
Nattokinase was dissolved in phosphate buffer solution at a concentration of 50 FU/mL.
0.2 And 2 mL nattokinase solution is added into the gel, and the gel is incubated for 30 minutes at 37 ℃, so that the gel can be observed to be completely degraded by the nattokinase and is in a cell suspension state.
The resuscitated cell suspension without gel formation was also recorded as control 1.
And simultaneously adding an equivalent amount of nattokinase solution into the cell suspension subjected to recovery without gel formation for treating for the same time, and verifying the damage of the nattokinase to cells. Is designated as control group 2.
The cells were collected by centrifugation, and the results of counting the cells are shown in FIG. 7. Recovery (%) = (number of cells after sol/number of cells added) ×100. The recovery rate of control 1 was 100%, indicating that the counting method was correct. The number of recovered cells in control group 2 was 99.8%, indicating no significant damage to cells by the nattokinase solution. Cell recovery was 100.7% and 96.1% for the 2X 10 7/mL cell-gel group and 3X 10 7/mL cell-gel group, respectively. The cell freezing solution capable of forming gel can form effective package on most cells after forming gel.
Example 6
Cell cryopreservation solutions were prepared under the conditions of example 2. Adipose-derived mesenchymal stem cells were frozen at a frozen density of 2X 10 7/mL and 3X 10 7/mL, respectively. Sampling and resuscitating after 6 months of freezing.
A fibrinogen solution was prepared according to the conditions of example 2.
The resuscitated cell suspension and fibrinogen solution were removed using a twin mixer as described in example 2 to provide a gel containing cells.
The resuscitated cell suspension without gel formation was also recorded as control 1.
And simultaneously adding an equivalent amount of nattokinase solution into the cell suspension subjected to recovery without gel formation for treating for the same time, and verifying the damage of the nattokinase to cells. Is designated as control group 2.
The resulting cell gel was subjected to lysis treatment using a nattokinase solution under the conditions of example 4.
Cells were collected by centrifugation and cell viability was measured using AOPI. The results are shown in FIG. 8. The number of living cells in each group was >95%. The processes of cell cryopreservation, cell resuscitation and gel formation do not lead to significant cell death.
The centrifugally collected cells were stained using an Annexin-V-PI apoptosis staining kit and the staining results were detected by flow cytometry. The non-apoptotic cells are not stained by Annexin-V and PI, the non-Annexin-V stained by PI is necrotic cells or mechanically damaged cells, the non-PI stained by Annexin-V stained is early apoptotic cells, and the Annexin-V and PI are late apoptotic cells simultaneously. The results are shown in FIG. 9.
From the results, it can be seen that >92% of the cells are in the non-apoptotic state. That is, it is demonstrated that the processes of cell cryopreservation, cell resuscitation and gel formation using the cell cryopreservation solution do not cause significant damage to cells to cause apoptosis.
Example 7
The basic solvent of the cell cryopreservation solution prepared in this example is water, and the composition formula is shown in table 5 below:
and (3) placing the prepared cell frozen stock solution in a refrigerator at the temperature of 2-8 ℃ for precooling and preserving.
Adipose-derived mesenchymal stem cells were cultured in the same manner as in example 2, and the cell confluency was about 85% as observed by a microscope. Cells were then collected by digestion with recombinant trypsin (TryplE) and cell viability and cell density were calculated by acridine orange/propidium iodide (AO/PI) staining.
According to the cell counting result, taking living cells 3×10 7, centrifugally collecting, removing supernatant, slowly adding 3 mL prepared cell freezing solution into cell sediment, uniformly mixing to uniformly disperse the cells in the cell freezing solution, wherein the cell density is 1×10 7/mL.
The cell suspension was aliquoted into 3 cryopreservation tubes, 1 mL per tube.
And placing the freezing tube in a program cooling box, and then placing the program cooling box in a low-temperature refrigerator at-80 ℃. And taking the cell cryopreservation tube out of the program cooling box after 24 hours, and storing in a low-temperature refrigerator at the temperature of-80 ℃.
Sampling at 6 months, taking out the frozen storage tube from the refrigerator, and rapidly melting in a water bath kettle at 37 ℃.
A fibrinogen solution was prepared as shown in table 6 below, with water as the solvent:
1 mL of the formulated fibrinogen solution was aspirated into a2 mL syringe.
The thawed 1 mL cell suspension was aspirated into another 2 mL syringe.
Two syringes were placed on a plastic holder of a twin mixer and connected to a Y-extension tube, while pushing out the two components to form a gel completely free of flow in about 3 minutes.
The gel was placed in a 24-well culture plate, a cell complete medium was added, and after culturing for 24 hours, the gel containing cells was stained with Calcein/propidium iodide (Calcein-AM/PI) cell activity and toxicity detection kit, and the photograph of the gel was shown under a fluorescence microscope as shown in fig. 10. It can be seen that the vast majority of cells in the gel are living cells (stained green) and only a small number of cells are dead cells (stained red). This result demonstrates that the use of the cell cryopreservation solution to cryopreserve cells and the gel formed during use can maintain the activity of the cells in a simulated physiological environment.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (11)
1. A cell freezing solution comprises dimethyl sulfoxide, soluble calcium salt and thrombin,
Wherein, the concentration of the dimethyl sulfoxide in the cell freezing solution is 0.01-10% v/v; the concentration of thrombin is 1-100 IU/mL; the concentration of the soluble calcium salt is 1-60 mM;
the soluble calcium salt includes one or more of calcium chloride, calcium bromide, calcium nitrate, calcium bicarbonate, and calcium dihydrogen phosphate.
2. The cell cryopreservation solution of claim 1, further comprising at least one of a permeable cryopreservation protectant, an impermeable cryopreservation protectant, a buffer solution, and a physiological solution.
3. The cell cryopreservation solution of claim 2, wherein the buffer solution comprises a phosphate buffer solution, a HEPES buffer solution, or Hank's buffer solution;
The physiological solution comprises physiological saline or glucose injection;
the permeable cryopreservation protective agent comprises propylene glycol or ethanol;
The impermeable cryopreservation protective agent comprises albumin, trehalose, dextran, polyethylene glycol, dextran, sucrose and hydroxyethyl starch.
4. The cell cryopreservation solution of claim 2, wherein the cell cryopreservation solution comprises 0.01-10% v/v dimethyl sulfoxide, 1-60 mmol/L calcium chloride, 1-100 IU/mL thrombin, 0.01-0.5 mmol/L glucose, 1-10% w/v dextran, 0.01-5% v/v propylene glycol, and 1-10% w/v albumin.
5. Use of a cell cryopreservation solution according to any one of claims 1-4 for cryopreserving cells or for forming a gel material, said gel material encapsulating cells.
6. The use according to claim 5, wherein the cell density in the cell cryopreservation solution is 1 x 10 7/mL~5×107/mL; and/or the cells comprise stem cells.
7. A composition for forming a gel, the composition comprising the cell cryopreservation solution of any one of claims 1-3 and a fibrinogen solution comprising fibrinogen and a solvent;
wherein, in the fibrinogen solution, the concentration of the fibrinogen is 5-100 mg/mL;
the mixing volume ratio of the cell freezing solution to the fibrinogen solution is 1: (0.5-2).
8. The composition of claim 7, wherein the solvent comprises physiological saline, water for injection, or phosphate buffer solution.
9. A cell preparation prepared from the composition of claim 7 or 8, said cell preparation being in the form of a gel.
10. A method of preparing a cell preparation according to claim 9, comprising thawing said cell frozen stock in which cells are frozen and mixing with said fibrinogen solution to form a gel.
11. Use of a cell cryopreservation solution according to any one of claims 1 to 4, a composition according to claim 7 or 8 or a cell preparation according to claim 9 or a cell preparation obtained by a method of preparation according to claim 10 for the preparation of a medicament for cell therapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410406620.9A CN117981747B (en) | 2024-04-07 | 2024-04-07 | Cell freezing solution and application thereof in cell preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410406620.9A CN117981747B (en) | 2024-04-07 | 2024-04-07 | Cell freezing solution and application thereof in cell preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117981747A CN117981747A (en) | 2024-05-07 |
CN117981747B true CN117981747B (en) | 2024-06-14 |
Family
ID=90891069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410406620.9A Active CN117981747B (en) | 2024-04-07 | 2024-04-07 | Cell freezing solution and application thereof in cell preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117981747B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103648507A (en) * | 2010-12-30 | 2014-03-19 | 人类起源公司 | Methods for cryopreserving and encapsulating cells |
CN105746493A (en) * | 2016-03-29 | 2016-07-13 | 深圳爱生再生医学科技有限公司 | Frozen-preserving and thawing method for microencapsulation immune cells |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335508B2 (en) * | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
CN106538512B (en) * | 2016-10-08 | 2019-07-30 | 北京汉氏联合干细胞研究院有限公司 | A kind of active stem cell gel preparation of holding freeze-stored cell and its application |
CN113507921A (en) * | 2019-03-21 | 2021-10-15 | 安特罗根有限公司 | Injectable composition containing mesenchymal stem cell-hydrogel and preparation, freezing and unfreezing methods thereof |
WO2021050896A1 (en) * | 2019-09-13 | 2021-03-18 | Lonza Ltd | Method of producing lyophilized cells |
CN115590811A (en) * | 2022-09-29 | 2023-01-13 | 中国药科大学(Cn) | Hydrogel preparation loaded with stem cells and application thereof |
-
2024
- 2024-04-07 CN CN202410406620.9A patent/CN117981747B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103648507A (en) * | 2010-12-30 | 2014-03-19 | 人类起源公司 | Methods for cryopreserving and encapsulating cells |
CN105746493A (en) * | 2016-03-29 | 2016-07-13 | 深圳爱生再生医学科技有限公司 | Frozen-preserving and thawing method for microencapsulation immune cells |
Also Published As
Publication number | Publication date |
---|---|
CN117981747A (en) | 2024-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Magnetic induction heating of superparamagnetic nanoparticles during rewarming augments the recovery of hUCM-MSCs cryopreserved by vitrification | |
JP3165863B2 (en) | Cryopreservation solution | |
CN106982821A (en) | Umbilical cord mesenchymal stem cells clinic freezes protection liquid composition and application thereof | |
CN106465710B (en) | Adipose tissue cryopreservation liquid and adipose tissue cryopreservation method | |
CN109090100A (en) | A kind of mesenchymal stem cell cryopreserving liquid and preparation method thereof and application method | |
JP2009269930A (en) | Preservation of non-embryonic cell from non-hematopoietic tissue | |
JP7401865B2 (en) | Methods for obtaining enriched populations of functional mesenchymal stem cells, cells obtained thereby, and compositions comprising the cells | |
KR101321144B1 (en) | Vitrification medium for stem cells and vitrification method for stem cells using the same | |
AU2002326901A1 (en) | Preservation of non embryonic cells from non hematopoietic tissues | |
CN104145943A (en) | Cryopreservation protection liquid for Wharton jelly tissues of human umbilical cord and preparation and application of cryopreservation protection liquid | |
CA2719806A1 (en) | Method, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
CN110800733A (en) | Cryopreservation solution and kit for umbilical cord mesenchymal stem cells | |
CN111838139A (en) | Protein-free cell cryopreservation liquid and application thereof | |
CN101070534B (en) | Method for freezing preservation nervous stem cells | |
RU2433173C1 (en) | Method of cryoconservation of multipotent mesenchymal stromal cells | |
CN111602648A (en) | Immune cell serum-free cryopreservation liquid and cryopreservation method | |
CN117981747B (en) | Cell freezing solution and application thereof in cell preparation | |
CN112106765A (en) | Stem cell protection solution and stem cell preservation method | |
US20200383317A1 (en) | Viable cell compositions, and methods related to same | |
CN111374123B (en) | Use method of neutral amino acid as cell cryoprotectant and application thereof | |
Grossfeld | Metachromasia in the living cell. | |
RU2303631C1 (en) | Method for production of mesenchymal stem cells and biotransplant using the same | |
WO2024143453A1 (en) | Cell composition | |
CN117099772A (en) | Cell cryopreservation liquid, preparation method of cell cryopreservation liquid and cell cryopreservation method | |
CN118266457A (en) | Ultralow-temperature preservation method for corneal endothelial cells, cryoprotectant and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |